Research & Development
UTR Therapeutics' UTRxMYCN M1-14 receives US FDA Orphan Drug Designation and Rare Pediatric Disease Designation
30 September 2026 - UTR Therapeutics Inc, a New York-based biotech company, announced on Tuesday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to 3'UTRMYCN M1...
Vanda Pharmaceuticals reports positive Phase III results for HETLIOZ in Delayed Sleep-Wake Phase Disorder
30 September 2026 - US pharmaceutical company Vanda Pharmaceuticals Inc (Nasdaq:VNDA) on Tuesday reported positive topline results from its pivotal Phase III study of HETLIOZ (tasimelteon) 20mg in adu...
Egetis Therapeutics receives FDA approval for EMCITATE in MCT8 deficiency
29 September 2026 - Life science investor Flerie AB (STO:FLERIE) announced on Tuesday that its portfolio company Egetis Therapeutics AB (STO:EGTX), a Swedish pharmaceutical company, has received US Fo...
AstraZeneca invests USD2bn in Summit Therapeutics to advance ADC and cancer-drug combinations
29 September 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) announced on Tuesday that it has agreed to invest USD2bn in newly issued equity in biopharmaceutical oncolo...
BRC Therapeutics participates in regulators' workshop advancing botanical drug development
29 September 2026 - BRC Therapeutics (BRC), a clinical-stage pharmaceutical company developing multimodal cannabinoid therapeutics for neurological and inflammatory conditions, announced on Monday its...
Lupin announces receipt of US FDA tentative approval for Apixaban Oral Suspension
28 September 2026 - Pharmaceutical company Lupin Limited (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) reported on Monday that it has received tentative US Food and Drug Administra...